Price of Hepatitis C Drug Zepatier to Be Reduced by 60%

In a press release issued earlier this month, Merck pharmaceuticals announced that they are lowering the cost of Zepatier, a medication used to treat hepatitis C genotypes 1 and 4.1

Commitment to lower drug costs

According to the Centers for Disease Control and Prevention, over 3.5 million people in the United States have chronic Hepatitis C, with 70% of cases considered genotype 1.2 Following a 2017 commitment to lower out-of-pocket drug costs, Merck now announced that the cost of Zepatier will be reduced by 60%.

The company also announced that the costs of several other medications will be reduced by 10%, and that they will not raise the average net price of prescription drugs across the company’s portfolio (except to account for inflation). Merck’s decision follows recent trends by other pharmaceutical companies, including commitments by Novartis, Pfizer, Roche, and Bayer to delay or halt planned drug-price increases.3 According to the press release, Merck will continue to “look for opportunities to further reduce costs for patients and the healthcare system”.4

About Zepatier

Zepatier was approved for its current usage by the Food & Drug Administration in 2016, and is typically prescribed for a period of 12 to 16 weeks.5 Like other combination, direct-acting antivirals, Zepatier can be highly effective in a short amount of time, especially as compared to non-combination or older treatments. However, with limited generic options available, direct-acting antivirals remain expensive, and many patients struggle to pay for the often out-of-pocket treatment.6

For help paying for Zepatier, including co-pay assistance, check out Merck’s Access Program, or consider these resources paying for treatment and managing health insurance.

View References

Comments

Poll